Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00162058 | A Phase II Study of DMP 115 to Assess Focal Liver Lesions | PHASE2 | COMPLETED | 80 | — | — | Mar 1, 2004 | Apr 1, 2006 | Aug 18, 2011 | 1 | United Kingdom |
| Name | Type | Description |
|---|---|---|
| Peflutren Lipid Microsphere Injectable Suspension | DRUG | - |
Inclusion Criteria: * Diagnosed with 1 but \<7 focal liver lesions * Scheduled for liver biopsy within 30 days of study * Scheduled for CT or MR within 30 days of study Exclusion Criteria: * Critically ill subjects * Subjects with right-to-left shunts